| New York Panel Set for Another Hearing on Franchise
The New York Senate Standing Committee on Racing, Gaming, and Wagering will hold the first of three public hearings on the future of the Thoroughbred racing franchise in the state Sept. 27. The hearing will be conducted at 11 a.m. EDT in Hearing Room A of the Legislative Office Building in Albany, the state capital. During the hearing, legislators will review Gov. Eliot Spitzer’s franchise recommendations and his memorandum of understanding with the New York Racing Association, which he has selected to continue operating Aqueduct, Belmont Park, and Saratoga. The committee also will discuss economic and regulatory issues related to Spitzer’s recommendation. Paul Francis, director of the Division of the Budget, and Patrick Foye, downstate chairman of the Empire State Development Corp., will outline and comment on the recommendations, according to a release from Sen.
Update: FETCH! Pet Care(TM) Expands Into Central Spokane County, Washington
FETCH! Pet Care, America's largest and most sophisticated pet care franchise offering professional pet sitting and dog walking services, today announced it has launched a new location in Washington's Central Spokane County region to provide area residents with unsurpassed pet care services. This new franchise marks the 100th FETCH! Pet Care location that, in aggregate, now services more than 7,500 active clients throughout 1,200 cities and towns in 31 states across the U.S. .
Epigenomics, Abbott to develop in vitro diagnostic test for colorectal cancer detection
Epigenomics AG has signed a non-exclusive strategic collaboration and license agreement in molecular diagnostics with Abbott, a global healthcare company. Under the agreement, Abbott and Epigenomics intend to develop an in vitro diagnostic blood test for the early detection of colorectal cancer based on Epigenomics' proprietary DNA methylation biomarker Septin9.
According to a press release issued by Epigenomics, the companies will launch a CE-marked test in Europe in 2009 followed by regulatory filing for US approval in 2010. Under the terms of the agreement, Epigenomics will receive an upfront fee, milestone payments and royalties on product sales.
The agreement also contains provisions for the evaluation by Abbott of some of Epigenomics' other proprietary biomarkers for additional cancer indications.
|
